antibody–drug conjugates (ADCs). A structure-based and parallel medicinal chemistry approach was applied to the synthesis of novel tubulysin analogues. These efforts led to the discovery of a number of novel and potent cytotoxic tubulysin analogues, providing a framework for our simultaneous report, which highlights the discovery of tubulysin-based ADCs, including use of site-specific conjugation to address
天然产物的微管溶素类药物因其对多种人类癌
细胞系的有效细胞毒性,包括在多重耐药性癌症模型中的显着活性,而引起了药物
化学界的广泛关注。由于其效力,微管溶素已成为靶向治疗的重要工具,在新型小分子药物结合物(SMDC)和
抗体-药物结合物(ADC)的开发中被广泛用作有效负载。基于结构和并行的药物
化学方法被应用于新型微管溶素类似物的合成。这些努力导致发现了许多新颖且有效的细胞毒性微管溶素类似物,为我们的同步报告提供了一个框架,该报告着重介绍了基于微管溶素的ADC的发现,